Towards simultaneous quantification of protease inhibitors and inflammatory biomarkers in serum for people living with HIV

2020 ◽  
Vol 12 (14) ◽  
pp. 1882-1888
Author(s):  
Pengyi Wang ◽  
Charles S. Venuto ◽  
Raymond Cha ◽  
Benjamin L. Miller
Keyword(s):  
Protease Inhibitor ◽  
Protease Inhibitors ◽  
Inflammatory Biomarkers ◽  
People Living With Hiv ◽  
Inflammatory Biomarker ◽  
Simultaneous Quantification ◽  
Living With Hiv

Detecting small and big molecules together: simultaneous quantification of protease inhibitor (DRV) and inflammatory biomarker in serum by Arrayed Imaging Reflectometry (AIR).

scholarly journals Correction: Towards simultaneous quantification of protease inhibitors and inflammatory biomarkers in serum for people living with HIV

2020 ◽  
Vol 12 (16) ◽  
pp. 2196-2196
Author(s):  
Pengyi Wang ◽  
Charles S. Venuto ◽  
Raymond Cha ◽  
Benjamin L. Miller
Keyword(s):  
Protease Inhibitors ◽  
Inflammatory Biomarkers ◽  
People Living With Hiv ◽  
Simultaneous Quantification ◽  
Living With Hiv

Correction for ‘Towards simultaneous quantification of protease inhibitors and inflammatory biomarkers in serum for people living with HIV’ by Pengyi Wang et al., Anal. Methods, 2020, DOI: 10.1039/d0ay00098a.

scholarly journals The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Alison K. Yoder ◽  
David S. Lakomy ◽  
Yongquan Dong ◽  
Suchismita Raychaudhury ◽  
Kathryn Royse ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Cancer Treatment ◽  
Protease Inhibitors ◽  
Anal Cancer ◽  
Anal Carcinoma ◽  
People Living With Hiv ◽  
Anal Squamous Cell Carcinoma ◽  
Free Survival ◽  
Cox Regression Analysis ◽  
Living With Hiv

Abstract Background The incidence of anal squamous cell carcinoma has been increasing, particularly in people living with HIV (PLWH). There is concern that radiosensitizing drugs, such as protease inhibitors, commonly used in the management of HIV, may increase toxicities in patients undergoing chemoradiation. This study examines treatment outcomes and toxicities in PLWH managed with and without protease inhibitors who are receiving chemoradiation for anal cancer. Methods Patient demographic, HIV management, and cancer treatment information were extracted from multiple Veterans Affairs databases. Patients were also manually chart reviewed. Among PLWH undergoing chemoradiation for anal carcinoma, therapy outcomes and toxicities were compared between those treated with and without protease inhibitors at time of cancer treatment. Statistical analysis was performed using chi-square, Cox regression analysis, and logistic regression. Results A total of 219 PLWH taking anti-retroviral therapy undergoing chemoradiation for anal cancer were identified and included in the final analysis. The use of protease inhibitors was not associated with any survival outcome including colostomy-free survival, progression-free survival, or overall survival (all adjusted hazard ratio p-values> 0.05). Regarding toxicity, protease inhibitor use was not associated with an increased odds of hospitalizations or non-hematologic toxicities; however, protease inhibitor use was associated with increased hospitalizations for hematologic toxicities, including febrile neutropenia (p < 0.01). Conclusion The use of protease inhibitors during chemoradiation for anal carcinoma was not associated with any clinical outcome or increase in non-hematologic toxicity. Their use was associated with increased hospitalizations for hematologic toxicities. Further prospective research is needed to evaluate the safety and efficacy of protease inhibitors for patients undergoing chemoradiation.

scholarly journals An observational study of the prevalence of metabolic syndrome in treatment-experienced people living with HIV in Singapore

PLoS ONE ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. e0252320
Author(s):  
Li Wei Ang ◽  
Oon Tek Ng ◽  
Irving Charles Boudville ◽  
Yee Sin Leo ◽  
Chen Seong Wong
Keyword(s):  
Metabolic Syndrome ◽  
Protease Inhibitors ◽  
Drug Effects ◽  
People Living With Hiv ◽  
Strand Transfer ◽  
Metabolic Complications ◽  
Obesity And Diabetes ◽  
Living With Hiv

Background While the use of combination antiretroviral therapy (cART) has conferred significant reduction in morbidity and mortality, there are growing concerns about the metabolic complications of antiretroviral regimens in HIV-infected patients. The aim of this study was to estimate the prevalence of metabolic syndrome (MetS) among people living with HIV (PLHIV) in Singapore. Methods We conducted a retrospective study using the clinical database maintained by the Clinical HIV Programme at the National Centre for Infectious Diseases, Singapore. Treatment-experienced PLHIV on follow-up during 2015–2017 were included. MetS was defined as having three or more of the following five abnormalities: hypertriglyceridemia, HDL hypocholesterolemia, hypertension, obesity, and diabetes. Results A total of 2,231 PLHIV were included in this study. 93.9% were men, and the median age at latest follow-up was 48 years. The median duration of HIV infection and duration of exposure to cART was 6.8 years and 5.7 years, respectively. All had been exposed to nucleoside reverse transcriptase inhibitors (NRTIs) as the first line of treatment, 93.9% to non-NRTIs, 28.6% to protease inhibitors (PIs) and 12.8% to integrase strand transfer inhibitors. The most common metabolic abnormality among PLHIV was HDL hypocholesterolemia (60.2%) followed by hypertriglyceridemia (45.5%). Of all the 2,231 individuals, 68.8% had at least one component of MetS. The overall prevalence of MetS was 23.6% (95% confidence interval 21.9%–25.4%). Of the 526 with MetS, the most common combination was HDL hypocholesterolemia, hypertriglyceridemia and hypertension (51.0%), followed by HDL hypocholesterolemia, hypertriglyceridemia, hypertension and diabetes (25.1%). Compared with PLHIV without MetS, a significantly higher proportion of those with MetS were ever on protease inhibitors (33.5% vs. 27.1%). Conclusion MetS is common in PLHIV. In view of the progressive aging of HIV-infected population and long-term use of cART, regular monitoring for metabolic abnormalities, surveillance of drug effects and behavioural interventions are needed to optimize management and prevention of metabolic disorders in PLHIV.

scholarly journals 1014. Factors Associated with Switching from Tenofovir Diproxil Phosphate to a Tenofovir Alafenamide Based Regimen in a Cohort with Unrestricted Access to Care and Medications

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S536-S536
Author(s):  
Anuradha Ganesan ◽  
SeungHyun Won ◽  
Evan C Ewers ◽  
William Bradley ◽  
Christina Schofield ◽  
...  
Keyword(s):  
Access To Care ◽  
Protease Inhibitors ◽  
People Living With Hiv ◽  
Hiv Diagnosis ◽  
Factors Associated ◽  
Us Military ◽  
Fda Approval ◽  
Unrestricted Access ◽  
Tenofovir Alafenamide ◽  
Living With Hiv

Abstract Background Background- Tenofovir alafenamide (TAF) is associated with fewer renal and bone toxicities than tenofovir disoproxil phosphate (TDF). Hence, most experts suggest switching to TAF. We examined factors associated with switching to TAF in the US Military HIV Natural History Study (NHS), a cohort of people living with HIV who have unrestricted access to care and medications. Methods Methods- The first formulation of TAF received FDA approval on 1 November 2015; hence, we included all NHS participants with visits between November 2015 and March 2019. Patient factors including race, gender, CD4 count, antiretroviral therapies (ART), viral load, HIV diagnosis era, presence of comorbidities (cancer, heart disease, dyslipidemia, kidney disease and obesity), were assessed for association with a switch to TAF with a logistic regression model. Results Results- Of the 1678 eligible participants, 1324 (63%) had received a TDF-based regimen. Participants who received a TDF-regimen were 94% male 44% African-American [AA], 39% Caucasians and 17% Hispanic. About half the participants who received TDF-based ART switched to a TAF-based regimen (n=682, 52%). Of the 425 (32%) participants receiving TDF/FTC co-formulated with efavirenz, 48% (n=206) switched to TAF. The proportions switching to TAF were higher in those receiving TDF/FTC co-formulated with rilpivirine [59%, n=90] or elvitegravir/cobicistat [68%, n=146]. The common ART regimens after the switch were: TAF co-formulated with elvitegravir/cobicistat (46%), rilpivirine (16%) or bictegravir (12%) and TAF/FTC combined with dolutegravir (15%). In an adjusted analysis, older participants, and participants receiving TDF/FTC in combination with efavirenz, dolutegravir, raltegravir, boosted protease inhibitors or a combination of boosted protease inhibitors and integrase inhibitors (other) were less likely to switch, table 1. Conclusion Conclusions- Despite the unrestricted access to care and ART in the NHS, only half of the participants switched to TAF. Participants on efavirenz-containing regimens were less likely to switch to a TAF-based regimen, possibly due to the lack of a co-formulated single tablet. These trends need to be followed and barriers to switching to TAF (both patient and provider) need examination. Table 1- Factors associated with switching to a Tenofovir Alafenamide Based Regimen Disclosures All Authors: No reported disclosures

Sign in / Sign up

Export Citation Format

Share Document